{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:41:06Z","timestamp":1760964066810,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.soc.2023.12.009","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T08:49:12Z","timestamp":1706345352000},"page":"447-466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Multidisciplinary Lymphoma and Myeloma Management for Surgeons"],"prefix":"10.1016","volume":"33","author":[{"given":"William B.","family":"Pearse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin G.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.soc.2023.12.009_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.soc.2023.12.009_bib2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.soc.2023.12.009_bib3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by","volume":"133","author":"Brady","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.soc.2023.12.009_bib4","unstructured":"SEER Preliminary Cancer Incidence Rate Estimates for 2017, and diagnosis years 2000 to 2017, SEER 18, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/statistics\/preliminary-estimates\/, based on the February 2019 SEER data submission and the November 2018 SEER data submission. Posted to the SEER web site, September 2019."},{"key":"10.1016\/j.soc.2023.12.009_bib5","doi-asserted-by":"crossref","first-page":"796962","DOI":"10.3389\/fonc.2021.796962","article-title":"Diffuse Large B-Cell Lymphoma: Clinical Presentation and Treatment Outcomes From the","volume":"11","author":"Nair","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.soc.2023.12.009_bib6","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/1097-0142(19821215)50:12<2699::AID-CNCR2820501202>3.0.CO;2-A","article-title":"Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute","volume":"50","author":"Anderson","year":"1982","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.soc.2023.12.009_bib7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajh.24937","article-title":"Follicular lymphoma: 2018 update on diagnosis and management","volume":"93","author":"Freedman","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.soc.2023.12.009_bib8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2967\/jnumed.122.264106","article-title":"Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical)","volume":"64","author":"Ricard","year":"2023","journal-title":"J\u00a0Nucl Med"},{"issue":"11","key":"10.1016\/j.soc.2023.12.009_bib9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"8","key":"10.1016\/j.soc.2023.12.009_bib10","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00277-016-2704-0","article-title":"Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma-experience at the Lymph Node Registry Kiel","volume":"95","author":"Johl","year":"2016","journal-title":"Ann Hematol"},{"issue":"24","key":"10.1016\/j.soc.2023.12.009_bib11","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood.2022015520","article-title":"Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey","volume":"140","author":"Syrykh","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.soc.2023.12.009_bib12","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.1016\/j.clml.2019.11.013","article-title":"Diagnosing Lymphoproliferative Disorders Using Core Needle Biopsy Versus Surgical Excisional Biopsy: Three-Year Experience of a Reference Center in Lebanon","volume":"20","author":"Assaf","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.soc.2023.12.009_bib13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-065X.1998.tb01446.x","article-title":"Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes","volume":"162","author":"Stevenson","year":"1998","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.soc.2023.12.009_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/10428194.2022.2140281","article-title":"A\u00a0multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double\/triple-hit lymphoma","volume":"64","author":"Cortese","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"10.1016\/j.soc.2023.12.009_bib15","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"6769","key":"10.1016\/j.soc.2023.12.009_bib16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.soc.2023.12.009_bib17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.soc.2023.12.009_bib18","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.soc.2023.12.009_bib19","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.soc.2023.12.009_bib20","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.soc.2023.12.009_bib21","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin's lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.soc.2023.12.009_bib22","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdn760","article-title":"Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type","volume":"20","author":"Stathis","year":"2009","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.soc.2023.12.009_bib23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.6004\/jnccn.2015.0075","article-title":"Hodgkin lymphoma, version 2.2015","volume":"13","author":"Hoppe","year":"2015","journal-title":"J\u00a0Natl Compr Canc Netw"},{"year":"2023","series-title":"Key statistics for Hodgkin lymphoma","key":"10.1016\/j.soc.2023.12.009_bib24"},{"issue":"1","key":"10.1016\/j.soc.2023.12.009_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis","volume":"15","author":"Huang","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.soc.2023.12.009_bib26","doi-asserted-by":"crossref","first-page":"485071","DOI":"10.1155\/2015\/485071","article-title":"The role of radiotherapy in Hodgkin's lymphoma: what has been achieved during the last 50 years?","volume":"2015","author":"Witkowska","year":"2015","journal-title":"BioMed Res Int"},{"issue":"12","key":"10.1016\/j.soc.2023.12.009_bib27","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","article-title":"Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions","volume":"24","author":"Klimm","year":"2013","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.soc.2023.12.009_bib28","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A\u00a0prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.soc.2023.12.009_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.soc.2023.12.009_bib30","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.soc.2023.12.009_bib31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.soc.2023.12.009_bib32","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.soc.2023.12.009_bib33","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.soc.2023.12.009_bib34","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.soc.2023.12.009_bib35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.soc.2023.12.009_bib36","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1182\/blood-2017-05-784678","article-title":"Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma","volume":"130","author":"Connors","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.soc.2023.12.009_bib37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.6004\/jnccn.2018.0013","article-title":"NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018","volume":"16","author":"Hoppe","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.soc.2023.12.009_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389201003379059","article-title":"Rituximab: the first monoclonal antibody approved for the treatment of lymphoma","volume":"1","author":"Grillo-L\u00f3pez","year":"2000","journal-title":"Curr Pharm Biotechnol"},{"issue":"23","key":"10.1016\/j.soc.2023.12.009_bib39","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2023.12.009_bib40","unstructured":"Seer Data. Available at: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2016\/."},{"issue":"6","key":"10.1016\/j.soc.2023.12.009_bib41","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.soc.2023.12.009_bib42","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated Diagnostic Criteria and Staging System for Multiple Myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"18","key":"10.1016\/j.soc.2023.12.009_bib43","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.soc.2023.12.009_bib44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-017-0549-1","article-title":"Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel","volume":"11","author":"Caers","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"19","key":"10.1016\/j.soc.2023.12.009_bib45","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2020008737","article-title":"How I treat AL amyloidosis","volume":"139","author":"Palladini","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.soc.2023.12.009_bib46","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/jcp.56.6.406","article-title":"Bone marrow immunohistology of plasma cell neoplasms","volume":"56","author":"Wei","year":"2003","journal-title":"J\u00a0Clin Pathol"},{"issue":"9","key":"10.1016\/j.soc.2023.12.009_bib47","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.3324\/haematol.2018.190181","article-title":"mutated and wild-type Waldenstr\u00f6m's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in","volume":"103","author":"Guerrera","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.soc.2023.12.009_bib48","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1309\/BVT4-YP41-LCV2-5GT0","article-title":"Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in\u00a0situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens","volume":"116","author":"Athanasiou","year":"2001","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.soc.2023.12.009_bib49","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1046\/j.1365-2141.1999.01204.x","article-title":"Expression of PRAD1\/cyclin D1 in plasma cell malignancy: incidence and prognostic aspects","volume":"104","author":"Sonoki","year":"1999","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.soc.2023.12.009_bib50","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/0959-8049(93)90071-M","article-title":"Karyotype in multiple myeloma and plasma cell leukaemia","volume":"29A","author":"Weh","year":"1993","journal-title":"Eur J Cancer"},{"issue":"26","key":"10.1016\/j.soc.2023.12.009_bib51","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2023.12.009_bib52","unstructured":"Seer Data. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"issue":"1","key":"10.1016\/j.soc.2023.12.009_bib53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.soc.2023.12.009_bib54","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","article-title":"Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group","volume":"101","author":"Tsang","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2023.12.009_bib55","doi-asserted-by":"crossref","unstructured":"Tanrivermis Sayit A, Elmali M, G\u00fcn S. Evaluation of Extramedullary Plasmacytoma of the Larynx with Radiologic and Histopathological Findings. Radiologia (Engl Ed). 2020:S0033-8338(20)30121-1. doi: 10.1016\/j.rx.2020.07.006.","DOI":"10.1016\/j.rx.2020.07.006"},{"key":"10.1016\/j.soc.2023.12.009_bib56","doi-asserted-by":"crossref","first-page":"895765","DOI":"10.1100\/2012\/895765","article-title":"A\u00a0review for solitary plasmacytoma of bone and extramedullary plasmacytoma","volume":"2012","author":"Kilciksiz","year":"2012","journal-title":"ScientificWorld J"},{"issue":"16","key":"10.1016\/j.soc.2023.12.009_bib57","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.19.00394","article-title":"Progression Risk Stratification of Asymptomatic Waldenstr\u00f6m Macroglobulinemia","volume":"37","author":"Bustoros","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2023.12.009_bib58","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-3-319-13150-4_7","article-title":"Biology, prognosis, and therapy of waldenstr\u00f6m macroglobulinemia","volume":"165","author":"Castillo","year":"2015","journal-title":"Cancer Treat Res"},{"issue":"1","key":"10.1016\/j.soc.2023.12.009_bib59","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MOG.0000000000000687","article-title":"Ileo-colonic lymphoma: presentation, diagnosis, and management","volume":"37","author":"Panneerselvam","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"issue":"3","key":"10.1016\/j.soc.2023.12.009_bib60","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/neuonc\/noy192","article-title":"Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma","volume":"21","author":"Grommes","year":"2019","journal-title":"Neuro Oncol"},{"issue":"8 Suppl","key":"10.1016\/j.soc.2023.12.009_bib61","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1614::AID-CNCR12>3.0.CO;2-2","article-title":"Orthopedic surgical management of skeletal complications of malignancy","volume":"80","author":"Harrington","year":"1997","journal-title":"Cancer"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105532072300100X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105532072300100X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:07:29Z","timestamp":1760962049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105532072300100X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S105532072300100X"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2023.12.009","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Multidisciplinary Lymphoma and Myeloma Management for Surgeons","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2023.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}